Track Bristol-Myers Squibb's net tangible assets ($22B) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2026), BMY shows a net tangible assets of $22B. That compares with $63B in the prior-year period — down 64.5% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, BMY's net tangible assets is now $22B (was $63B) — a 64.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Bristol-Myers Squibb is outperforming or lagging.
Tracking BMY's net tangible assets over time shows whether Bristol-Myers Squibb is scaling, shrinking, or reshaping that part of the business. The current reading is $22B That compares with $63B in the prior-year period — down 64.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this net tangible assets page, Stockcircle has Bristol-Myers Squibb's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $22B) with ownership activity and broader fundamentals.
Bristol-Myers Squibb's net tangible assets is $22B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.